BioCentury | Apr 26, 2019
Emerging Company Profile

ProNeurogen: Angiotensin peptides for vascular cognitive impairment

By developing native and glycosylated forms of the angiotensin-(1-7) peptide for vascular cognitive impairment, ProNeurogen hopes to plug a treatment gap that repurposed Alzheimer's disease drugs have failed to fill. There are no therapies approved...
BC Week In Review | Oct 19, 2018
Company News

Gurnet to acquire Corium as it heads for NDA

Healthcare investor Gurnet Point Capital will acquire drug delivery company Corium International Inc. (NASDAQ:CORI) for $12.50 per share in cash plus $0.50 per share in a contingent value right (CVR). The deal, including the CVR,...
BioCentury | Apr 6, 2018

Smid-cap smorgasbord

While the biggest milestone of the second quarter came early and turned out to be a disappointment, investors still have plenty to look forward to in immuno-oncology. In addition, specialist investors’ current strategy of overweighting...
BioCentury | Jan 6, 2018

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
BioCentury | Oct 28, 2017

Biogen doubles down

Shares of Biogen Inc. were buffeted last week by a pair of poorly understood moves intended to improve the big biotech’s share of profits for aducanumab, along with lower than expected revenues for newly launched...
BC Week In Review | Sep 29, 2017
Clinical News

Axovant discontinuing intepirdine for AD after Phase III miss

Axovant Sciences Ltd. (NYSE:AXON) said it will discontinue development of intepirdine (RVT-101) to treat mild to moderate Alzheimer’s disease after the product missed the co-primary endpoints in the Phase III MINDSET trial in the indication....
BC Extra | Sep 26, 2017
Clinical News

Axovant plummets after intepirdine AD miss

Axovant Sciences Ltd. (NYSE:AXON) fell $17.92 (74%) to $6.33 on Tuesday after discontinuing development of intepirdine (RVT-101) to treat mild to moderate Alzheimer’s disease after the product missed the co-primary endpoints in the Phase III...
BioCentury | Jul 21, 2017
Product Development

Surrogate start

Phase II results for Probiodrug AG ’s Alzheimer’s disease candidate point to potential surrogate markers for improvements in cognition that one day could be used in early development to handicap the likelihood of success in...
BioCentury | Jul 8, 2017

A clinical quarter

Buysiders will find themselves digesting at least 23 Phase III data readouts in the next quarter, two of which could provide clarity on increasingly competitive markets in lung cancer and hemophilia. The third quarter is...
BC Week In Review | May 12, 2017
Company News

Adamas, HCR in $100M royalty deal

Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) will receive a loan worth up to $100 million via a royalty note deal with HealthCare Royalty Partners (Stamford, Conn.). The company is to receive $35 million up front and $65...
Items per page:
1 - 10 of 235